Qiagen (QGEN) Projected to Post Earnings on Wednesday

Qiagen (NYSE:QGEN) will likely be posting its Q4 2025 results after the market closes on Wednesday, February 4th. Analysts expect Qiagen to post earnings of $0.59 per share and revenue of $528.5340 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 5, 2026 at 9:30 AM ET.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.03. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The company had revenue of $532.58 million during the quarter, compared to the consensus estimate of $525.68 million. During the same quarter in the previous year, the firm posted $0.60 earnings per share. Qiagen’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, analysts expect Qiagen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Qiagen Price Performance

Shares of QGEN stock opened at $54.26 on Wednesday. The company has a market cap of $11.46 billion, a P/E ratio of 28.01, a PEG ratio of 2.60 and a beta of 0.66. The stock’s 50-day moving average is $49.19 and its 200 day moving average is $49.56. Qiagen has a 1-year low of $39.61 and a 1-year high of $57.81. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.60 and a quick ratio of 2.30.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on QGEN shares. Barclays restated an “overweight” rating and issued a $57.89 target price (up previously from $55.79) on shares of Qiagen in a research note on Monday, December 15th. UBS Group restated a “neutral” rating on shares of Qiagen in a research note on Wednesday, January 21st. Wall Street Zen lowered Qiagen from a “buy” rating to a “hold” rating in a research report on Saturday, January 10th. Deutsche Bank Aktiengesellschaft lowered shares of Qiagen from a “buy” rating to a “hold” rating and raised their price target for the stock from $52.00 to $54.00 in a research report on Thursday, January 22nd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Qiagen in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $53.04.

Institutional Investors Weigh In On Qiagen

A number of hedge funds have recently modified their holdings of QGEN. Danske Bank A S purchased a new position in Qiagen during the third quarter worth about $36,000. Advisory Services Network LLC purchased a new stake in shares of Qiagen during the 3rd quarter valued at approximately $64,000. EverSource Wealth Advisors LLC lifted its holdings in Qiagen by 226.4% in the second quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock valued at $125,000 after acquiring an additional 1,802 shares during the last quarter. Osaic Holdings Inc. increased its stake in Qiagen by 101.4% during the second quarter. Osaic Holdings Inc. now owns 3,875 shares of the company’s stock worth $185,000 after acquiring an additional 1,951 shares during the last quarter. Finally, Pitcairn Co. acquired a new stake in Qiagen during the second quarter worth $208,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.